Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947893599> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2947893599 abstract "e16504 Background: Sipuleucel-T is an autologous cellular immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. In IMPACT (NCT00065442), a phase 3 trial, sipuleucel-T-induced immune responses against target Ag prostatic acid phosphatase (PAP) or PA2024, a recombinant protein consisting of PAP and granulocyte macrophage colony stimulating factor, correlated with OS (Sheikh 2013). Additionally, sipuleucel-T-induced immunoglobulin G (IgG) responses against secondary, non-target Ag (i.e. Ag spread) and the breadth of Ag spread also correlated with improved OS (GuhaThakurta 2015). Here we assessed Ag spread and OS in real-world patients from PRIME (NCT01727154), an immune monitoring sub-study of sipuleucel-T trials Methods: IgG levels in pre and wk 6 (2 wk post sipuleucel-T completion) sera from PRIME (n = 100) were quantified using Luminex xMAP. IgG responses to secondary Ag (LGALS3, PSA, KLK2, LGALS8, K-Ras, E-Ras) were defined as ≥ 1.5-fold increase over baseline. OS associations with individual Ag responses and total number of Ag per patient were assessed using the Kaplan-Meier method. Hazard ratios (HR) were estimated using a Cox Proportional Hazard Model. Results: IgG responses to ≥1 secondary Ag were observed in ≥72% of patients. Individual IgG responses to LGALS3, K-Ras, and LGALS8 at wk 6 were significantly associated with OS. Furthermore, breadth of Ag spread positively correlated with OS (Table); as the total number of Ag responses per patient increased, OS improved compared to patients with no secondary IgG responses. Conclusions: The results presented are consistent with findings from the prior phase 3 trial IMPACT. Secondary Ag responses were generated in real-world patients treated with sipuleucel-T, and these responses correlated with OS. Furthermore, breadth of Ag spread also correlated with improved OS. Clinical trial information: NCT01727154. [Table: see text]" @default.
- W2947893599 created "2019-06-07" @default.
- W2947893599 creator A5016944058 @default.
- W2947893599 creator A5024685539 @default.
- W2947893599 creator A5030609617 @default.
- W2947893599 creator A5041066937 @default.
- W2947893599 creator A5041779826 @default.
- W2947893599 creator A5042114199 @default.
- W2947893599 creator A5059219836 @default.
- W2947893599 creator A5064023036 @default.
- W2947893599 creator A5064449830 @default.
- W2947893599 date "2019-05-20" @default.
- W2947893599 modified "2023-09-23" @default.
- W2947893599 title "Antigen (Ag) spread after sipuleucel-T and correlation with overall survival (OS): A real-world experience." @default.
- W2947893599 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e16504" @default.
- W2947893599 hasPublicationYear "2019" @default.
- W2947893599 type Work @default.
- W2947893599 sameAs 2947893599 @default.
- W2947893599 citedByCount "0" @default.
- W2947893599 crossrefType "journal-article" @default.
- W2947893599 hasAuthorship W2947893599A5016944058 @default.
- W2947893599 hasAuthorship W2947893599A5024685539 @default.
- W2947893599 hasAuthorship W2947893599A5030609617 @default.
- W2947893599 hasAuthorship W2947893599A5041066937 @default.
- W2947893599 hasAuthorship W2947893599A5041779826 @default.
- W2947893599 hasAuthorship W2947893599A5042114199 @default.
- W2947893599 hasAuthorship W2947893599A5059219836 @default.
- W2947893599 hasAuthorship W2947893599A5064023036 @default.
- W2947893599 hasAuthorship W2947893599A5064449830 @default.
- W2947893599 hasConcept C117220453 @default.
- W2947893599 hasConcept C126322002 @default.
- W2947893599 hasConcept C143998085 @default.
- W2947893599 hasConcept C147483822 @default.
- W2947893599 hasConcept C203014093 @default.
- W2947893599 hasConcept C2524010 @default.
- W2947893599 hasConcept C33923547 @default.
- W2947893599 hasConcept C71924100 @default.
- W2947893599 hasConceptScore W2947893599C117220453 @default.
- W2947893599 hasConceptScore W2947893599C126322002 @default.
- W2947893599 hasConceptScore W2947893599C143998085 @default.
- W2947893599 hasConceptScore W2947893599C147483822 @default.
- W2947893599 hasConceptScore W2947893599C203014093 @default.
- W2947893599 hasConceptScore W2947893599C2524010 @default.
- W2947893599 hasConceptScore W2947893599C33923547 @default.
- W2947893599 hasConceptScore W2947893599C71924100 @default.
- W2947893599 hasLocation W29478935991 @default.
- W2947893599 hasOpenAccess W2947893599 @default.
- W2947893599 hasPrimaryLocation W29478935991 @default.
- W2947893599 hasRelatedWork W1572585889 @default.
- W2947893599 hasRelatedWork W2051729664 @default.
- W2947893599 hasRelatedWork W2068785421 @default.
- W2947893599 hasRelatedWork W2080388405 @default.
- W2947893599 hasRelatedWork W2118999172 @default.
- W2947893599 hasRelatedWork W2218620360 @default.
- W2947893599 hasRelatedWork W2249095293 @default.
- W2947893599 hasRelatedWork W2318101661 @default.
- W2947893599 hasRelatedWork W2560500500 @default.
- W2947893599 hasRelatedWork W2560699986 @default.
- W2947893599 hasRelatedWork W2589216838 @default.
- W2947893599 hasRelatedWork W2590392578 @default.
- W2947893599 hasRelatedWork W2602658142 @default.
- W2947893599 hasRelatedWork W2891002453 @default.
- W2947893599 hasRelatedWork W2906673642 @default.
- W2947893599 hasRelatedWork W3088579092 @default.
- W2947893599 hasRelatedWork W3162395554 @default.
- W2947893599 hasRelatedWork W91773918 @default.
- W2947893599 hasRelatedWork W2172263434 @default.
- W2947893599 hasRelatedWork W2182895745 @default.
- W2947893599 isParatext "false" @default.
- W2947893599 isRetracted "false" @default.
- W2947893599 magId "2947893599" @default.
- W2947893599 workType "article" @default.